Ikarian Capital, LLC has filed its 13F form on May 16, 2024 for Q1 2024 where it was disclosed a total value porftolio of $754 Million distributed in 137 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Crinetics Pharmaceuticals, Inc. with a value of $30.1M, Tarsus Pharmaceuticals, Inc. with a value of $25.8M, Sarepta Therapeutics, Inc. with a value of $19.7M, Aerovate Therapeutics, Inc. with a value of $10.9M, and Alpine Immune Sciences, Inc. with a value of $10.4M.

Examining the 13F form we can see an decrease of $4.87M in the current position value, from $759M to 754M.

Ikarian Capital, LLC is based out at Dallas, TX

Below you can find more details about Ikarian Capital, LLC portfolio as well as his latest detailed transactions.

Portfolio value $754 Million
Healthcare: $678 Million
ETFs: $66.4 Million
Real Estate: $9.45 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 137
  • Current Value $754 Million
  • Prior Value $759 Million
  • Filing
  • Period Q1 2024
  • Filing Date May 16, 2024
  • Form Type 13F-HR/A
  • Activity in Q1 2024
  • New Purchases 0 stocks
  • Additional Purchases 0 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 1 stocks
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.